Association Aamong Ppolymorphisms in the Aapoptosis‐Rrelated <scp>NKX3</scp> ‐1, Caspase‐3, Caspase‐9, and <scp>BCL</scp> ‐2 Genes and Prostate Cancer Susceptibility From 9706 Cases and 12,567 Controls

Yanyan Feng, Zhong-Wen Feng, Dan Li, Jiandong Gui, Zhihong Song, Xiaohua Xie, Lijie Zhu, Yuanyuan MiCancer 2025 · DOI

TL;DR

This meta-analysis investigated the association between genetic variations (polymorphisms) in key apoptosis-related genes (NKX3-1, Caspase-3, Caspase-9, and BCL-2) and prostate cancer (PCa) risk. The study found that specific polymorphisms in NKX3-1 and Caspase-9 are associated with an increased risk of PCa, while a polymorphism in Caspase-3 is linked to a reduced risk, offering potential biomarkers for PCa susceptibility.

What Problem Does This Paper Address?

Prostate cancer (PCa) is a leading cause of cancer-related deaths globally, with its incidence influenced by a complex interplay of genetic and environmental factors. While apoptosis (programmed cell death) is a crucial process for maintaining cellular health and preventing cancer, its dysregulation is a hallmark of many malignancies, including PCa. This allows cancer cells to evade death, proliferate, and spread. Researchers have identified several genes involved in apoptosis pathways, such as NKX3-1, Caspase-3, Caspase-9, and BCL-2, as potential contributors to PCa susceptibility. However, the clinical relevance of specific genetic variations (polymorphisms) within these genes and their association with PCa risk has remained inconclusive due to varying results across individual studies. This paper aims to address this gap by conducting a comprehensive meta-analysis to provide more precise estimates of these associations.

Methods

The researchers employed a systematic meta-analysis approach to pool data from multiple case-control studies. They conducted a thorough literature search across major databases (PubMed, Web of Science, Google Scholar, Embase, Cochrane Library, and SinoMed) using specific keywords related to apoptosis genes and prostate cancer. Studies were included if they were case-control designs, focused on the association between specific apoptosis-related gene polymorphisms and PCa risk, and provided sufficient genotype data. Data extraction was performed by two independent investigators. Statistical analyses involved calculating odds ratios (ORs) with 95% confidence intervals (CIs) to assess the association between polymorphisms and PCa risk. Heterogeneity among studies was evaluated using the Q-test, and fixed-effects or random-effects models were applied accordingly. Various genetic models (allelic, heterozygous, homozygous, dominant, and recessive) were used to examine the associations. Additionally, bioinformatics analyses using the 1000 Genomes Browser and TCGA database were performed to assess allele frequencies and gene expression patterns.

Datasets

The primary "datasets" for this meta-analysis were derived from 22 published case-control studies that met the inclusion criteria. These studies collectively included 9706 cases of prostate cancer and 12,567 controls. The 1000 Genomes Browser was used to obtain allele frequency data for the studied SNPs across different global populations. The Cancer Genome Atlas (TCGA) database was utilized to analyze gene expression levels of CASP3 and BCL2 in PCa tumors and normal tissues.

Key Insights and Ideas

  • Apoptosis Genes as PCa Risk Factors: The study reinforces the critical role of apoptosis pathways in PCa development and progression.
  • Specific SNPs as Biomarkers: The identification of specific single nucleotide polymorphisms (SNPs) within NKX3-1 and Caspase-9 as risk factors, and a Caspase-3 SNP as a protective factor, suggests their potential utility as biomarkers for predicting PCa susceptibility.
  • Gene-Gene Interactions: The exploration of gene-gene interaction networks highlights how these apoptosis-related genes may work in concert with other genes (like AR, SPDEF, AKT1, TMPRSS2) to influence PCa development.
  • Ethnic Variations: While not the primary focus, the study acknowledges that ethnic differences in PCa incidence exist and that future research should consider these variations in genetic association studies.

Key Results

The meta-analysis identified several significant associations:

  • Increased PCa Risk:
    • NKX3-1 rs2228013 polymorphism was associated with an increased risk of PCa (OR = 1.18, 95% CI = 1.00-1.38).
  • CASP9 rs1052571 polymorphism was associated with an increased risk of PCa (OR = 1.19, 95% CI = 1.01-1.40).
  • CASP9 rs4645982 polymorphism was associated with an increased risk of PCa (OR = 1.41, 95% CI = 1.03-1.93).
  • Reduced PCa Risk:
    • CASP3 rs4647603 polymorphism was associated with a reduced risk of PCa across multiple genetic models (e.g., GG vs. AA: OR = 0.44, 95% CI = 0.26-0.75; G-allele vs. A-allele: OR = 0.82, 95% CI = 0.68-0.99).
  • Gene Expression Insights: TCGA data indicated elevated CASP3 expression and downregulated BCL2 expression in PCa tumors compared to normal tissues. Higher NKX3-1 expression was also trended towards better disease-free survival.

Limitations and Future Work

The authors acknowledge several limitations:

  • HWE Deviations: Two of the included studies did not conform to Hardy-Weinberg equilibrium (HWE) in their control groups, which could potentially affect the reliability of the findings.
  • Gene-Environment Interactions: The meta-analysis did not fully account for gene-environment interactions or other covariates, which could influence PCa risk.
  • Limited Gene Coverage: The study focused on only four apoptosis-related genes, and many other genes involved in apoptosis pathways (e.g., BRAC gene) were not included.

Future work should focus on:

  • Larger-Scale Studies: Conducting larger, prospective studies to validate these findings and confirm the role of these and other apoptosis-related gene polymorphisms in PCa onset and progression.
  • Comprehensive Genetic Analysis: Investigating a broader range of apoptosis-related genes and their polymorphisms.
  • Incorporating Covariates: Future research should aim to incorporate gene-environment interactions and other relevant covariates to provide a more complete understanding of PCa risk.
  • Personalized Medicine: The identified SNPs hold promise for developing personalized screening strategies and clinical management approaches for PCa patients.

Summary updated

Abstract

These findings provide strong evidence for the potential contributions of polymorphisms in the apoptosis-related caspase-3, caspase-9, and NKX3-1 genes in the onset and progression of PCa.
BibTeX
@inproceedings{feng2025association,
  author = {Yanyan Feng and Zhong-Wen Feng and Dan Li and Jiandong Gui and Zhihong Song and Xiaohua Xie and Lijie Zhu and Yuanyuan Mi},
  title = {{Association Aamong Ppolymorphisms in the Aapoptosis‐Rrelated <scp>NKX3</scp> ‐1, Caspase‐3, Caspase‐9, and <scp>BCL</scp> ‐2 Genes and Prostate Cancer Susceptibility From 9706 Cases and 12,567 Controls}},
  booktitle = {Cancer},
  year = {2025},
  doi = {10.1002/cnr2.70206},
}
Figure